Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

28-03-2024(Thu) 27-03-2024(Wed) 26-03-2024(Tue) 25-03-2024(Mon) 22-03-2024(Fri)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
24 May, 2021 (Monday)

            
BEIGENE(6160)
Analysis¡G
BeiGene (6160) is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and expand access for patients worldwide. It has built state-of-the-art biologic and small molecule manufacturing facilities in China to support the potential future demand of our products, and it also works with high quality contract manufacturing organizations (¡§CMOs¡¨) to manufacture its internally developed clinical and commercial products. Additionally, it has entered into collaborations with world-leading biopharmaceutical companies such as Amgen and Novartis to develop and commercialize innovative medicines globally. As of end of December 2020, it had over 45 products and product candidates in commercial stage or clinical development, including 7 approved medicines, 5 pending approval, and over 30 in clinical development. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $200, Target Price: $230, Cut Loss Price: $185


INNOVENT BIO(1801)
Analysis¡G
Innovent Bio (1801.HK) recently announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (¡§NSCLC¡¨). This is the first U.S. regulatory submission of sintilimab, a PD-1 inhibitor being developed and commercialized under a global collaboration agreement between the Company and Eli Lilly and the Group (¡§Lilly¡¨). The Company believes the acceptance of the first regulatory submission for sintilimab in the U.S. and outside of China represents an encouraging start for the Company`s and Lilly`s collaborative efforts to make sintilimab available in countries beyond China, as the collaboration continues to pursue opportunities globally for this immuno-oncology medicine across various tumor types. To date, sintilimab has two indications approved in China, three regulatory submissions under review in China, one regulatory submission under review in U.S. and is currently being evaluated in a wide variety of cancer types under a broad clinical development program.
Strategy¡G
Buy-in Price: $90.00, Target Price: $100.00, Cut Loss Price: $85.00



FLAT GLASS (6865.HK) - Cost Advantages Will Be Prominent as the Price of Photovoltaic Glass Falls

Investment Summary

Results in 21Q1 Soar Again, up 289%

Benefiting from the continuation of the industry's high boom and the launch of new production lines, Flat Glass recorded operating revenue of RMB2,057 million in the first quarter of 2021, up by 70.95%yoy. The net profit attributable to the parent company was RMB838 million, up by 289.38% yoy and up by 2.6% qoq, hitting new record high again.

Profitability Indices Hit New High

In the first quarter, the price of photovoltaic glass remained in a high range between RMB40 and RMB32 per square meter, which was approximately RMB11 to RMB14 higher than the same period in previous years. It is a prerequisite for photovoltaic glass manufacturers to maintain high profitability. In terms of product mix, the proportion of thin glass with high gross margin increased to over 30% by 19 ppts yoy. The continued optimization of the product mix increased the gross margin. The Company recorded a 58.2% gross margin in the first quarter, an increase of 18.4 ppts yoy, and a slightly decrease of 0.3 ppts qoq.

The Company displayed good performance in period expense ratio. The sales, administrative, R&D and financial expense ratios changed by -1.5 ppts, +0.7 ppts, +0.9 ppts, and -2.1 ppts, respectively. The administrative expenses increased, mainly due to the rise in share incentives and employee salaries. The R&D expenses climbed mainly because of more R&D projects. The main reason for the decrease in financial expenses was the decrease in interest expenses and the growth in exchange gains.

The final net profit margin was 40.74%, up by 22.9 ppts yoy and up by 4.33 ppts qoq. The profitability indices all hit record highs. After the completion of the RMB2.5 billion A-share private placement, the Company's balance sheet has become strong. Meanwhile, the Company increased the reserves and inventories of some raw materials to prepare for future fluctuations.

Cost Advantages Will Be Prominent as the Price of Photovoltaic Glass Falls

In February, the Company announced proposed issuance of no more than 76 million H shares for replenishing working capital. This will help the Company further strengthen its asset structure.

On March 29, the Company announced that it would invest RMB5.8 billion to add six new production lines with production capacity of 1,200 tons per day (two production lines in Jiaxing + four production lines in Anhui). The production lines are expected to be put into production in 2022-2023. At the end of 2020, the Company's production capacity was approximately 6,400 tons per day. The current production capacity is 8,600 tons per day. By the end of this year, the production capacity is expected to reach 12,200 tons per day. After full production, the Company's total production capacity is expected to reach 19,400 tons per day, with its leading position more stabilized.

In terms of costs, the Company will construct a pipeline project of direct supply of natural gas with the terminal as the Anhui production line, to further strengthen its future control of costs and consolidate its cost advantages.

From the end of March to early April, with the rapid release of industry supply, the downstream gradually entered the off-season, and the demand growth rate slowed down. The Company took the initiative to significantly lower product prices by approximately 30%. It is expected to ease downstream cost pressures and increase demand. On the other hand, it will also help restrain the excessive expansion of the industry production capacity and optimize the industry supply. Benefiting from the advantages in technology, scale, capital and customers, the Company's cost advantages will become more prominent as market price falls. Its market share is expected to increase.

Investment Thesis

Despite the recent price drop, the photovoltaic industry remains enthusiasm in the long run. We are optimistic about the company's future expectations. Taking into account the market price adjustment and the construction of new production capacity, we adjusted our profit forecast and adjusted the target price to HK$ 33, equivalent to 2021/2022 E 26.3/18.8x P/E and 12.5/9/6.8x P/B, BUY rating. (Closing price as at 20 May 2021)

Financials

Click Here for PDF format...




Recommendation on 24-5-2021
RecommendationBUY
Price on Recommendation Date$ 22.050
Suggested purchase priceN/A
Target Price$ 33.000
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2021 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]